Vergelijking

Elamipretide vs. Pasireotid

Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.

Identiteit

Categorie

Onderzoek (overig)

CAS-nr.

736992-21-5

396091-73-9

Molecuulmassa

639.8 g/mol

1047.21 g/mol

Halfwaardetijd

geen gegevens

Sequentie

D-Arg-Dmt-Lys-Phe-NH2

geen gegevens

Werkingsmechanisme

Elamipretide

Elamipretide is a cell-permeable tetrapeptide with alternating aromatic and basic residues that selectively concentrates on cardiolipin — a phospholipid found almost exclusively in the inner mitochondrial membrane that is important for cristae curvature and the organisation of the respiratory-chain complexes. By binding cardiolipin, elamipretide is proposed to stabilise cristae architecture, support electron transport and ATP production, and reduce the formation of reactive oxygen species. These mechanistic models derive largely from cell and animal models and biophysical work; the extent to which they explain clinical efficacy in humans is, given the mixed trial results, a matter of ongoing research.

Pasireotid

Pasireotide binds more broadly than older somatostatin analogs (SSTR1/2/3/5) with particularly high affinity for SSTR5. This suppresses, among others, ACTH release in Cushing's disease and GH release in acromegaly.

Bewijsbasis

Hoogste bewijs

Humane RCT

Studies

waarvan bij mensen

Geregistreerde effecten

Openstaande tegenstrijdigheden

Gedocumenteerde bijwerkingen

Juridische status

Country	Elamipretide	Pasireotid
Duitsland	Niet goedgekeurd	Op recept
Verenigde Staten	Op recept	Op recept

Volledige vermeldingen

Elamipretide

Volledige vermelding →

Pasireotid

Volledige vermelding →

Frequently asked questions

What is the difference between Elamipretide and Pasireotid?: Elamipretide is classified as "Onderzoek (overig)", while Pasireotid is classified as "Onderzoek (overig)". Elamipretide: Elamipretide (SS-31, MTP-131, formerly Bendavia) is a synthetic, mitochondria-targeting tetrapeptide (sequence D-Arg-Dmt-Lys-Phe-NH2) that binds cardiolipin on the inner mitochondrial membrane and is proposed to stabilise cristae structure and support mitochondrial bioenergetics. It was investigated clinically by Stealth BioTherapeutics across several indications, including primary mitochondrial myopathy, Barth syndrome, heart failure, and dry age-related macular degeneration (geographic atrophy). The trial record is mixed, with several pivotal studies missing their primary endpoints. In September 2025 elamipretide (brand name Forzinity) received accelerated FDA approval in the United States solely for the ultra-rare Barth syndrome; for all other investigated indications it remains investigational and it is not approved as a medicine outside the United States. Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Elamipretide or Pasireotid?: The highest available evidence level is "Humane RCT" for Elamipretide and "Humane RCT" for Pasireotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Elamipretide and Pasireotid in Germany and the United States?: Duitsland: Elamipretide — Niet goedgekeurd, Pasireotid — Op recept. Verenigde Staten: Elamipretide — Op recept, Pasireotid — Op recept. These are factual summaries with source and review date on the individual pages.

Country

Elamipretide

Pasireotid

Duitsland

Niet goedgekeurd

Op recept

Verenigde Staten

Op recept

Frequently asked questions

What is the difference between Elamipretide and Pasireotid?

Elamipretide is classified as "Onderzoek (overig)", while Pasireotid is classified as "Onderzoek (overig)". Elamipretide: Elamipretide (SS-31, MTP-131, formerly Bendavia) is a synthetic, mitochondria-targeting tetrapeptide (sequence D-Arg-Dmt-Lys-Phe-NH2) that binds cardiolipin on the inner mitochondrial membrane and is proposed to stabilise cristae structure and support mitochondrial bioenergetics. It was investigated clinically by Stealth BioTherapeutics across several indications, including primary mitochondrial myopathy, Barth syndrome, heart failure, and dry age-related macular degeneration (geographic atrophy). The trial record is mixed, with several pivotal studies missing their primary endpoints. In September 2025 elamipretide (brand name Forzinity) received accelerated FDA approval in the United States solely for the ultra-rare Barth syndrome; for all other investigated indications it remains investigational and it is not approved as a medicine outside the United States. Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Elamipretide or Pasireotid?

The highest available evidence level is "Humane RCT" for Elamipretide and "Humane RCT" for Pasireotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Elamipretide and Pasireotid in Germany and the United States?

Duitsland: Elamipretide — Niet goedgekeurd, Pasireotid — Op recept. Verenigde Staten: Elamipretide — Op recept, Pasireotid — Op recept. These are factual summaries with source and review date on the individual pages.